 In a 1984 study, Judy reported that Coenzyme Q10 supplementation could help to offset the inhibitory effects of the chemotherapy drug adriamycin (doxorubicin) on the bio-synthesis of Coenzyme Q10 and could alleviate the cardio-toxicity of the drug.Adriamycin is an established chemotherapeutic drug with known anti-tumor effects; however, its use was limited by its documented cardio-toxicity at higher dosages.In the study, Judy and his co-researchers started the Coenzyme Q10 supplementation at a dosage of 100 milligrams per day three to five days before the adriamycin treatment began.